1011528-16-7Relevant articles and documents
Soluble guanylate cyclase stimulators for the treatment of hypertension: Discovery of MK-2947
Brockunier, Linda,Stelmach, John,Guo, Jian,Spencer, Tracy,Rosauer, Keith,Bansal, Alka,Cai, Sheng-Jian,Chen, Nancy,Cummings, John,Huang, Li,Johnson, Timothy,Levesque, Sonia,Luo, Lin,Maloney, Kevin,Metzger, Joseph,Mortko, Christopher,Ortega, Karen,Pai, Lee-Yuh,Pereira, Antonio,Salituro, Gino,Shang, Jackie,Shepherd, Cherrie,Sherrie Xu, Shiyao,Yang, Qifeng,Cui, Jisong,Roy, Sophie,Parmee, Emma,Raghavan, Subharekha
supporting information, (2020/10/12)
The NO-sGC-cGMP signaling pathway plays an important role in the cardiovascular system. Loss of nitric oxide tone or impaired signaling has been associated with cardiovascular diseases, such as hypertension, pulmonary hypertension and heart failure. Direct activation of sGC enzyme independent of NO represents a novel approach for modulating NO signaling with tremendous therapeutic potential. Herein, we describe the design of a structurally novel class of heme-dependent sGC stimulators containing the 3,3-dimethylpyrrolidin-2-one moiety which resulted in the identification of the potent, selective stimulator 30 (MK-2947) for the treatment of hypertension.
PYRAZOLOPYRIDINE, INDAZOLE, IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE, PYRAZOLOPYRAZINE AND PYRAZOLOPYRIDINE DERIVATIVES AS STIMULATORS OF GUANYLATE CYCLASE FOR CARDIOVASCULAR DISORDERS
-
Page/Page column 22, (2010/03/02)
The present application relates to novel azabicyclic compounds, processes for their preparation, their use alone or in combinations for the treatment and/or prevention of diseases, and their use for producing medicaments for the treatment and/or prevention of diseases, especially for the treatment and/or prevention of cardiovascular disorders.
